trending Market Intelligence /marketintelligence/en/news-insights/trending/cPb3hb957DzSHZrqdSRUwQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In this list

Eli Lilly: price it was paid for Humalog insulin fell 8.1% over past 5 years

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Eli Lilly: price it was paid for Humalog insulin fell 8.1% over past 5 years

Eli Lilly and Co. said the price it was paid for its Humalog insulin dropped 8.1% over the last five years after accounting for rebates and discounts, The Wall Street Journal reported March 24, citing information from the company.

The Indianapolis-based company said the net price for the widely-used insulin drug — the price after discounts and rebates — fell to an average of $135 a patient a month in 2018 from $147 in 2014, according to the report. Meanwhile, the product’s average list price rose 51.9% to $594 per patient monthly, the Journal reported.

Drugmakers like Lilly are facing scrutiny in the U.S. Congress over big increases in insulin drug prices.